Simulations Plus Inc. (NASDAQ: SLP) announced strategic collaboration programs with three pharmaceutical companies to integrate artificial intelligence into drug development workflows. The partnerships aim to advance AI-enabled modeling capabilities across the drug development process.

The collaborations will utilize Simulations Plus' software platforms including GastroPlus, MonolixSuite, ADMET Predictor, and Thales. Participating companies will integrate the company's AI agents into model-informed drug development workflows to enable natural language interaction, automate data processing, and coordinate simulations across multiple modeling engines.

"Our approach to AI is grounded in how it operates within a complete system, not as a standalone capability," said Jonathan Chauvin, Co-Chief Product & Technology Officer at Simulations Plus. "These collaborations will allow us to work alongside our partners, leveraging real-time scientific feedback and company data to continuously refine how workflows are orchestrated across our tools."

The programs will provide insight into AI integration in real-world pharmaceutical environments and inform product development, workflow standardization, and commercial models. The collaborations also include alignment with information technology teams to establish deployment, governance, and integration standards for AI capabilities within existing systems.

Chief Executive Officer Shawn O'Connor stated that the partnerships represent a move from experimentation to practical implementation of AI in drug development. The company positions itself as advancing software and services into a unified modeling ecosystem.

Simulations Plus develops model-informed and AI-accelerated drug development solutions for the pharmaceutical industry. The company provides software and consulting services for drug discovery, development, and commercialization.